Quotables
"During my service in the United States Congress, I took the initiative in creating the Internet."
Al Gore ; The basis for the later misquote by US Republicans that Gore had "invented" the Internet. Gore was the leading political champion of the modern-day Internet.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120129860 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative... | 05/24/2012 |
| 20120129800 | Agent For Preventing And Treating Pityriasis Versicolor The present invention concerns an agent for prevention and treatment of pityriasis. The agent according to the present invention comprises at least one transaminase inhibitor effectively inhibiting the transamination process which is of pat... | 05/24/2012 |
| 20120070496 | ANTIDEPRESSANT DOSAGE FORM A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of time in a therapeutically responsive dose to produce antidepressant therapy... | 03/22/2012 |
| 20120071560 | MONOAMINE REUPTAKE INHIBITORS The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be... | 03/22/2012 |
| 20120070369 | HIF INHIBITORS AND USE THEREOF The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.... | 03/22/2012 |
| 20120039958 | COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHY Provided are electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegen... | 02/16/2012 |
| 20120028912 | Methods of modulating bromodomains The present invention features compounds useful for and methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods for treating HIV infection and HIV related disease.... | 02/02/2012 |
| 20120022086 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing a catecholamine backbone and pharmaceutically accept... | 01/26/2012 |
| 20110319494 | Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. Th... | 12/29/2011 |
| 20110306675 | COMPOSITIONS AND METHODS FOR INHIBITING NF-KB MEDIATED TUMORIGENICITY AND ADHESION-DEPENDENT SURVIVAL OF CANCER CELLS Disclosed are compositions and methods for inhibiting NF-κB mediated cellular proliferation and metastasis. This abstract is intended to be used as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present inventi... | 12/15/2011 |
| 20110301452 | Microcapsule for local treatment of a tumor and method for positioning a magnetic gradient field guiding magnetic nanoparticles to a target location as well as apparatus for positioning a magnetic gradient field A microcapsule for the local treatment of a tumor is proposed. The microcapsule has a support material forming a casing for the microcapsule, an active agent that damages tumor cells, a marker material suitable for use as an x-ray marker, and at least one magnetic nanop... | 12/08/2011 |
| 20110300236 | Method of treating impaired mitochondrial function Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, ph... | 12/08/2011 |
| 20110269811 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). T... | 11/03/2011 |
| 20110257270 | DRUG FOR TREATMENT OF COLON CANCER A first aspect of the invention provides a method for treating, preventing or ameliorating a hyperproliferative disease and/or disorder in a mammal comprising administering to the mammal a therapeutically effective amount of one or more compounds selected from the group... | 10/20/2011 |
| 20110251243 | Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime A method of determining a personalised therapeutic regime, comprising: receiving genetic information relating to a patient; determining genetic criteria relevant to a personalised therapeutic regime for the patient using the genetic information; receiving personal infor... | 10/13/2011 |
| 20110212138 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be ... | 09/01/2011 |
| 20110206775 | Preparation of inert pharmaceutical excipients for stabilizing unstable pharmaceutical ingredients In a method of treating a pharmaceutical component, a reducing substance is added to a solution of water and a pharmaceutical excipient having at least one residual reactive impurity. The reducing substance is allowed to react with the residual reactive impurity, thereb... | 08/25/2011 |
| 20110207761 | Diversion- and/or abuse-resistant aompositions and methods for making the same A composition formulated for diversion- and/or abuse-resistance, includes at least one active pharmaceutical ingredient (API), each present in an acidic form, a first compound capable of coupling to the acidic form of the API to form a complex, where the resulting compl... | 08/25/2011 |
| 20110171297 | SUSTAINED RELEASE FORMULATION FOR VENLAFAXINE HYDROCHLORIDE The invention provides a sustained release composition that; (1). Is free of initially increased drug delivery that occurs (in sustained release systems containing the water soluble drug venlafaxine HCl, known as burst phenomenon, by using a functional core partially or... | 07/14/2011 |
| 20110172185 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a... | 07/14/2011 |
| 20110159050 | AMPHIPHILIC PROTEINS AS MORPHOLOGY MODIFIERS Disclosed is a process for modifying the morphology and/or polymorphism of an organic substance, which process comprises treating the solid substance, or a solution or dispersion thereof, with one or more amphiphilic proteins.... | 06/30/2011 |
| 20110152288 | METHODS OF TREATING VASOMOTOR SYMPTOMS The present invention relates to methods for treating, preventing or controlling vasomotor symptoms such as hot flashes comprising administering specific norepinephrine/serotonin reuptake inhibitors.... | 06/23/2011 |
| 20110152377 | EXTERNAL PREPARATION COMPRISING FATTY ACID SALT OR BENZOIC ACID SALT OF BASIC PHARMACOLOGICALLY ACTIVE COMPONENT, AND METHOD FOR PRODUCTION THEREOF It has been demanded to develop a formulation for a novel external preparation having excellent transdermal absorption of a basic pharmacologically active component contained therein. It is found that the lipid solubility (logP values) of a basic pharmacologically activ... | 06/23/2011 |
| 20110135695 | ORAL DOSAGE FORM FOR CONTROLLED DRUG RELEASE An oral dosage form comprising,
| |
| 20110130463 | DEUTERIUM-ENRICHED BUPROPION The present application describes deuterium-enriched bupropion, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... | 06/02/2011 |
| 20110117203 | PHARMACEUTICAL COMPOSITION CONTAINING WATER SOLUBLE DRUG The present invention is directed to a process of preparing beads coated with a water soluble drug for incorporation into a pharmaceutical composition comprising: (a) preparing a supersaturated drug solution containing a desired amount of drug, which is completely satur... | 05/19/2011 |
| 20110118357 | PROCESS FOR PREPARING O-DESMETHYLVENLAFAXINE The present invention provides a convenient and efficient process for the preparation of O-desmethylvenlafaxine (ODV), comprising the reaction of venlafaxine, or a salt thereof, with a thiol reagent such as a dithiol, an aminothiol or an inorganic thiol. The present inv... | 05/19/2011 |
| 20110112200 | SOLID STATES OF O-DESMETHYLVENLAFAXINE SALTS The present invention provides crystalline and amorphous salts of O-desmethylvenlafaxine and processes for preparing said salts of O-desmethylvenlafaxine. The present invention further provides pharmaceutical compositions comprising said salts of O-desmethylvenlafaxine.... | 05/12/2011 |
| 20110112073 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiom... | 05/12/2011 |
| 20110105619 | AMORPHOUS BUPROPION HYDROBROMIDE AND PREPARATION THEREOF The present invention provides an amorphous bupropion hydrobromide and an amorphous bupropion hydrobromide granulates with at least one pharmaceutically acceptable carrier, and a process for its preparation.... | 05/05/2011 |
| 20110098273 | Oligomer-Calcium Channel Blocker Conjugates The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the... | 04/28/2011 |
| 20110092468 | Pharmaceutical Calcimimetics This invention relates to novel calcimimetic compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of... | 04/21/2011 |
| 20110082213 | NOVEL SALTS OF O-DESMETHYL-VENLAFAXINE Novel pharmaceutically acceptable salts of desvenlafaxine with physiologically ubiquitous ions selected from sugar acids and vitamins, processes for their preparation, pharmaceutical compositions containing them and uses therefor are described.... | 04/07/2011 |
| 20110070300 | EXTENDED RELEASE DOSAGE FORMS OF METOPROLOL The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of... | 03/24/2011 |
| 20110071075 | PROMOTER FOR BICARBONATE SECRETION IN GASTROINTESTINAL TRACT A substance is described which can prevent or treat a disease associated with the secretion of an acid. A calcium receptor activator is the active ingredient in a composition which promotes bicarbonate secretion in a gastrointestinal tract. Examples of the calcium recep... | 03/24/2011 |
| 20110059905 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.... | 03/10/2011 |
| 20110059170 | METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a dif... | 03/10/2011 |
| 20110054037 | BIS-AROMATIC ANTICANCER AGENTS Treatment of cancer includes administering a compound of formula (I) to a subject. In particular, treatment of colorectal cancer is described.... | 03/03/2011 |
| 20110046146 | Phosphodiesterase 4 inhibitors PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R1, R2, R3and R4 are as defined herein. ... | 02/24/2011 |
| 20110021502 | USE OF CHOLINESTERASE INHIBITORS FOR TREATING VASCULAR DEPRESSION The invention discloses the use of cholinesterase inhibitors in treating vascular depression.... | 01/27/2011 |
